TrialCancer2023

A randomized Phase 2 study to compare erlotinib with or without bevacizumab in previously untreated patients with advanced non-small cell lung cancer with EGFR mutation.

Youngjoo Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.